Spectrum of cognitive impairment in neurocysticercosis Differences according to disease phase
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
05/11/2013
05/11/2013
2012
|
Resumo |
Objectives: Cognitive decline related to neurocysticercosis (NC) remains poorly characterized and underdiagnosed. In a cross-sectional study with a prospective phase, we evaluated cognitive decline in patients with strictly calcified form (C-NC), the epidemiologically largest subgroup of NC, and investigated whether there is a spectrum of cognitive abnormalities in the disease. Methods: Forty treatment-naive patients with C-NC aged 37.6 +/- 11.3 years and fulfilling criteria for definitive C-NC were submitted to a comprehensive cognitive and functional evaluation and were compared with 40 patients with active NC (A-NC) and 40 healthy controls (HC) matched for age and education. Patients with dementia were reassessed after 24 months. Results: Patients with C-NC presented 9.4 +/- 3.1 altered test scores out of the 30 from the cognitive battery when compared to HC. No patient with C-NC had dementia and 10 patients (25%) presented cognitive impairment-no dementia (CIND). The A-NC group had 5 patients (12.5%) with dementia and 11 patients (27.5%) with CIND. On follow-up, 3 out of 5 patients with A-NC with dementia previously still presented cystic lesions with scolex on MRI and still had dementia. One patient died and the remaining patient no longer fulfilled criteria for either dementia or CIND, presenting exclusively calcified lesions on neuroimaging. Conclusions: Independently of its phase, NC leads to a spectrum of cognitive abnormalities, ranging from impairment in a single domain, to CIND and, occasionally, to dementia. These findings are more conspicuous during active vesicular phase and less prominent in calcified stages. Neurology (R) 2012; 78: 861-866 Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Brazil Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Brazil Janssen-Cilag Janssen Cilag |
Identificador |
NEUROLOGY, PHILADELPHIA, v. 78, n. 12, supl., Part 1-2, pp. 861-866, MAR, 2012 0028-3878 http://www.producao.usp.br/handle/BDPI/41665 10.1590/S0004-282X2012000500018 |
Idioma(s) |
eng |
Publicador |
LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA |
Relação |
NEUROLOGY |
Direitos |
closedAccess Copyright LIPPINCOTT WILLIAMS & WILKINS |
Palavras-Chave | #ALZHEIMERS-DISEASE #BRAZIL #CYSTICERCOSIS #DISORDERS #NEUROLOGY #DEMENTIA #THERAPY #CERAD #CLINICAL NEUROLOGY |
Tipo |
article original article publishedVersion |